Altasciences acquires Alliance Contract Pharma

By Jenni Spinner contact

- Last updated on GMT

(Image/kirill4mula)
(Image/kirill4mula)

Related tags: Contract manufacturing, API, acquisition

The contract research organization has purchased Alliance Contract Pharma, a small-molecule contract manufacturing and analytical firm.

Altasciences is a mid-size CRO based in Quebec, Canada, that focuses on providing comprehensive early-stage drug development, going from lead candidate selection to proof of concept. Alliance Contract Pharma, based in Harleysville, PA, offers contract manufacturing of small-molecule products, as well as a range of analytical services.

By acquiring Alliance Contract Pharma, the company will add commercial manufacturing, GMP warehouse storage, and clinical supply distribution to its range of preclinical, clinical, and bioanalytical offerings.

Chris Perkin, CEO of Altasciences, said the acquisition will enable his company to offer a larger, more comprehensive range of services to its contract customers.

We remain committed to providing our clients with value-added services that create a new paradigm of drug development outsourcing​,” he said.

According to the company, sending data, projects, and/or methodologies between CROs, or among divisions within a large CRO, can be time-consuming and error-prone, and the process can lead to extended delays.

The company has recently executed a number of strategic acquisitions. These include the integration of their preclinical business in 2018, and now the purchase of Alliance Contract Pharma. Additionally, in February 2019, the company brought various divisions together and consolidated​.

Alliance Contract Pharma president Stephen Schweibenz said the deal offers opportunities for both companies.

We are excited to be joining a team that is responsive and understanding, and continuously looking to create innovative partnerships that redefine the status quo and address the challenges that our clients face in meeting critical milestones​,” Schweibenz said.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars